Results 101 to 110 of about 2,050 (152)

Gastrointestinal risk profile of tigecycline, omadacycline and eravacycline: Evidence from the FDA adverse event reporting system

Acta Pharmaceutica
This study assessed the gastrointestinal (GI) safety profiles of tigecycline, omadacycline, and eravacycline through a retrospective disproportionality analysis of reports submitted to the FDA Adverse Event Reporting System (FAERS) between the second ...
Wang Zhu, Gan Guoping, Yao Haiping
doaj   +1 more source

Efficacy and Safety of Eravacycline Combination Therapy for Carbapenem-Resistant Acinetobacter baumannii Pneumonia in ICU Patients: A Retrospective Study

Infection and Drug Resistance
Qingli Guo,1,* Yifei Wei,2,* Qiongrui Zhao,3 Wenping Zhang,4 Pin Lv,5 Zhimin Zhou,1 Shanmei Wang6 1Department of Clinical Laboratory, Xuchang People’s Hospital, Xuchang, Henan, People’s Republic of China; 2Department of Clinical ...
Guo Q, Wei Y, Zhao Q, Zhang W, Lv P, Zhou Z, Wang S   +6 more
doaj  

Eravacycline: Data Based on Real Evidence

Eravacycline, a novel synthetic fluorocycline, exhibits broad-spectrum antimicrobial activity against multidrug-resistant (MDR) Gram-positive, Gram-negative, and anaerobic bacteria, making it a promising option for complicated intra-abdominal infections (
Martini, L, De Cecchis, L, Giuliano, S, Flammini, Sarah, Lazzarotto, D, Zhanel, GG, Terrosu, G, Tascini, C, Prataviera, F, Moreal, C   +9 more
core  

Efficacy and safety of eravacycline versus tigecycline for complicated intra-abdominal infections in the ICU: a multicenter, single-blind, parallel randomized controlled trial study protocol

Frontiers in Medicine
BackgroundComplicated intra-abdominal infections (cIAIs), often caused by multidrug-resistant bacteria such as carbapenem-resistant A. baumannii (CRAB) and carbapenem-resistant Enterobacteriaceae (CRE) are a critical challenge in ICUs.
Jin Jie Liu, Dong Dong Guo, Meng Xing Wang, Yan Zhao Li, Hang Li, Si Bo Liu, Rong Li Yang, Dian Hong Zhang   +7 more
doaj   +1 more source

In Vitro Activities of Cefiderocol, Ceftazidime–Avibactam, Meropenem–Vaborbactam, Imipenem–Relebactam and Eravacycline Against Carbapenem-Resistant Klebsiella pneumoniae

AIM/BACKGROUND: Carbapenem-resistant Klebsiella pneumoniae (CRKP) infections are a significant global threat due to the limited treatment options. In this study, in vitro activities of novel antimicrobial agents were investigated against CRKP strains ...
FATMA SENA TÜRKDOĞAN, Betigul Ongen
core   +1 more source

Beyond β-Lactams: Defining the Role of Eravacycline in Multidrug-Resistant and Metallo-β-Lactamase-Producing Infections. [PDF]

Antibiotics (Basel)
Keck JM.
europepmc   +1 more source

<i>In vitro</i> activity of eravacycline and comparator agents against Gram-negative and Gram-positive bacteria: results from China Antimicrobial Surveillance Network between 2017 and 2019. [PDF]

JAC Antimicrob Resist
Ou H, Yang Y, Shen S, Ding L, Yin D, Han R, Hu F.   +6 more
europepmc   +1 more source

Eravacycline-Cefiderocol Combination Therapy for Carbapenem-Resistant <i>Acinetobacter baumannii</i> Infective Endocarditis: A Case Report and Brief Review of the Literature. [PDF]

Infect Drug Resist
Lou L, Li X, Zhang P, Wu H, Chen H, Ma J, Zhang K.   +6 more
europepmc   +1 more source

Hypofibrinogenemia Induced by Eravacycline: A Rare but Serious Adverse Effect of a Novel Antimicrobial Agent. [PDF]

Cureus
Khanal P, Sapkota S, Karageorgiou I, Al Baghdadi T.   +3 more
europepmc   +1 more source

Clinical outcomes and safety of eravacycline in hematology: a multicenter, real-world study. [PDF]

Antimicrob Agents Chemother
Wang J, Zhu J, Wu W, Luo R, Liu Z, Tong Z, Sun T, Xu Y, Wu D.   +8 more
europepmc   +1 more source